Histological Validation of dGEMRIC Indices as a Quantitative Biomarker for Cartilage Damage in the Hip Joint

Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Dec 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to measure cartilage damage in the hip joint, particularly for patients with advanced hip osteoarthritis who are planning to have hip replacement surgery. Researchers want to see if a specific MRI technique, called dGEMRIC, can accurately reflect the health of cartilage when compared to actual tissue samples taken during the surgery. This could help doctors better understand the condition of the cartilage and improve treatment options in the future.

To participate in this trial, you need to be between 65 and 74 years old and have advanced hip osteoarthritis. You should also have had an MRI of your hip that includes a special imaging sequence. However, you won’t be eligible if you’re under 18, have had previous hip surgeries, or have certain medical conditions that affect your hip. If you decide to join the trial, you can expect to provide informed consent and undergo the MRI before your surgery. This research could play a significant role in how doctors assess and treat hip issues moving forward.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with advanced hip osteoarthritis.
• • Preoperative hip MRI including biochemical sequence (MP2RAGE).
• • Indication for hip replacement.
• Exclusion Criteria:
• • Patients without informed consent.
• • Age under 18 years.
• • Insufficient language understanding in German, French, or English.
• • Previous hip surgeries.
• • Neoplastic and inflammatory comorbidities of the hip.
• • Post-traumatic or pediatric deformities.
• • Avascular necrosis of the femoral head.
• • Inadequate MRI image quality (motion artifacts, extra-articular contrast media administration, delay (\>45 minutes) between contrast injection and MRI imaging).